[HTML][HTML] The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
LF Reeskamp, TR Tromp… - Current opinion in …, 2020 - journals.lww.com
LF Reeskamp, TR Tromp, ESG Stroes
Current opinion in lipidology, 2020•journals.lww.comAngptl3 and apoC-III are novel targets in lipoprotein metabolism that reduce triglycerides
when inhibited. The expected CVD risk reduction may be mediated through reduced
triglyceride-rich lipoprotein particle number, reflected by apoB, rather than triglyceride
reduction per se. Limited human evidence shows that apoC-III and angptl3 inhibition both
potently lower triglycerides, but since angptl3 inhibition reduces apoB more robustly it may
be expected to confer more favorable CVD risk reduction.
when inhibited. The expected CVD risk reduction may be mediated through reduced
triglyceride-rich lipoprotein particle number, reflected by apoB, rather than triglyceride
reduction per se. Limited human evidence shows that apoC-III and angptl3 inhibition both
potently lower triglycerides, but since angptl3 inhibition reduces apoB more robustly it may
be expected to confer more favorable CVD risk reduction.
Summary
Angptl3 and apoC-III are novel targets in lipoprotein metabolism that reduce triglycerides when inhibited. The expected CVD risk reduction may be mediated through reduced triglyceride-rich lipoprotein particle number, reflected by apoB, rather than triglyceride reduction per se. Limited human evidence shows that apoC-III and angptl3 inhibition both potently lower triglycerides, but since angptl3 inhibition reduces apoB more robustly it may be expected to confer more favorable CVD risk reduction.
Lippincott Williams & Wilkins